Passage Bio
PASG
89 hedge funds and large institutions have $786M invested in Passage Bio in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 13 reducing their positions, and 3 closing their positions.
600% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 3
208% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more funds holding
Funds holding: 71 → 89 (+18)
0.67% more ownership
Funds ownership: 3.51% → 4.18% (+0.67%)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
4% less capital invested
Capital invested by funds: $817M → $786M (-$31.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$106M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$29.7M |
| 4 |
BlackRock
New York
|
+$16.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$8.25M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.68M |
| 3 |
Millennium Management
New York
|
-$2.75M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.57M |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$761K |
PASG Hedge Fund Activity: Q1 2021 in Review
89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q1 2021, worth a combined $786M — down 3.8% from $817M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PASG positions and 3 closed out — a net gain of 18 holders — while 40 added to existing stakes and 13 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $106M. The largest seller was RA Capital Management, exiting entirely with an estimated $8.25M sold.
- 89 institutional investors held Passage Bio (PASG) as of Q1 2021, up from 71 in Q4 2020.
- Funds reported $786M of Passage Bio stock for Q1 2021, down 3.8% quarter-over-quarter.
- 21 funds opened new Passage Bio positions in Q1 2021 and 3 closed out, a net change of +18 holders.
- The largest Passage Bio buyer in Q1 2021 was Versant Venture Management, an estimated $106M added.
- The largest Passage Bio seller in Q1 2021 was RA Capital Management, an estimated $8.25M sold.
Based on aggregated 13F filings for Q1 2021.